Decision Support

Anticoagulation therapy for the prevention of stroke and systemic embolism in atrial fibrillation.

References

BNF. www.bnf.org/www.medicinescomplete.com. Accessed on dates as indicated.

Connolly SJ, Ezekowitz MD, Yusuk S, et al. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). N Engl J Med 2009:361(12):1129-51. Epub 2009 Aug 30.

Corrigendum to: ‘Guidelines: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation’ Eur Heart J (2013) doi: 10.1093/eurheartj/eht291. First published online: 31 July 2013.

Eliquis (apixaban) Summary of Product Characteristics. www.medicines.org.uk. Accessed June 2015.

Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. European Heart Journal. 2012; 33(12):1500-1510.

Guidelines for the management of atrial fibrillation. European Heart Journal 2010; 31: 2369-2429.

Guidelines on Oral Anticoagulation with Warfarin—fourth edition. British Journal of Haematology 2011; 154: 311-324

Lixiana (edoxaban) Summary of Product Characteristics. www.medicines.org.uk. Accessed May 2016.

www.mdcalc.com. Accessed June 2015.

Medscape Drug Interaction Checker. Accessed October 2014.

National Institute for Health and Clinical Excellence. Atrial fibrillation: the management of atrial fibrillation. NICE clinical guideline 180. June 2014.

National Institute for Health and Clinical Excellence. Edoxaban for preventing stroke and stemic embolism in people with non-valvular atrial fibrillation. NICE technololgy appraisal guidance TA355. September 2015.

National Institute for Health and Clinical Excellence. Atrial fibrillation patient decision aid: medicines to help reduce your risk of a stroke – what are the options? NICE June 2014.

National Institute for Health and Clinical Excellence. Patient decision aid: user guide for healthcare professionals – Implementing the NICE guideline on atrial fibrillation (CG180). NICE June 2014.

NICE Implementation Collaborative. Consensus statement. Supporting local implementation of NICE guidance on the use of the novel (non-Vitamin K antagonist) oral anticoagulants in non-valvular atrial fibrillation. NICE June 2014.

Pradaxa (dabigatran etexilate) Summary of Product Characteristics. www.medicines.org.uk. Accessed June 2015.

Warfarin Summary of Product Charachteristics. www.medicines.org.uk. Accessed October 2014.

Xarelto (rivaroxaban) Summary of Product Characteristics. www.medicines.org.uk. Accessed June 2015.

Last updated on 25th July 2016, Version 1.1.0.

Developed as part of a joint working group initiative comprising the National Institute for Health and Care Excellence (NICE), Boehringer Ingelheim Ltd and Prescribing Decision Support Ltd at the Centre for Medicines Optimisation, Keele University.

Keele University and PDS Ltd reserves the right to update and change the Tool at any time in order to address changes in NICE clinical guidance and respective drug SPCs, improve functionality and reflect changing user and business needs.  Keele University / PDS Ltd also reserves the right to withdraw the Tool if and when its content is out of date and no longer consistent with NICE clinical guidance.

© 2016 Keele University
© 2016 Prescribing Decision Support Ltd